COVID19 India Update: Cipla to Sell Antiviral Drug Remdesivir as ‘Cipremi’

COVID19 India Update: Cipla to Sell Antiviral Drug Remdesivir as ‘Cipremi’

COVID19 India Update: Cipla to Sell Antiviral Drug Remdesivir as ‘Cipremi’

 

Cipla Limited on Sunday, June 21 announced the launch of the experimental anti-viral drug remdesivir named 'Cipremi'. Remdesivir is an antiviral medication happens to be the only USFDA approved Emergency Use Authorisation (EUA) treatment for Covid-19 patients in the country. 


The drug controller general of India has granted Cipla regulatory approval for the emergency use of medicine due to the urgency and unmet medical needs of the country as stated, the company in a statement.

Cipla will also provide training for the use of the drug and conduct phase IV clinical trials on the patients with the consent of the patients documented. 

 

“Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction.”
Umang Vohra MD and Global CEO, Cipla.

 

According to the reports of trials act-1 conducted with remdesivir on 1603 patients over 60 centers across the US, Europe, and Asia resulted in faster time to clinical recovery in hospitalized patients. 
Most of the patients' were on oxygen therapy of which some were on ventilators. 

This drug would be supplied through government and open markets to ensure equalized distribution.